WO2015059180A3 - Upconverting vesicles and uses - Google Patents

Upconverting vesicles and uses Download PDF

Info

Publication number
WO2015059180A3
WO2015059180A3 PCT/EP2014/072623 EP2014072623W WO2015059180A3 WO 2015059180 A3 WO2015059180 A3 WO 2015059180A3 EP 2014072623 W EP2014072623 W EP 2014072623W WO 2015059180 A3 WO2015059180 A3 WO 2015059180A3
Authority
WO
WIPO (PCT)
Prior art keywords
vesicles
upconverting
relates
present
triplet
Prior art date
Application number
PCT/EP2014/072623
Other languages
French (fr)
Other versions
WO2015059180A2 (en
WO2015059180A9 (en
Inventor
Sven H. C. ASKES
Sylvestre Bonnet
Original Assignee
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden filed Critical Universiteit Leiden
Publication of WO2015059180A2 publication Critical patent/WO2015059180A2/en
Publication of WO2015059180A3 publication Critical patent/WO2015059180A3/en
Publication of WO2015059180A9 publication Critical patent/WO2015059180A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6915—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to vesicles, such as liposomes and polymerosomes, for use in triplet-triplet annihilation upconversion (TTA-UC). The present invention also relates to the use of such vesicles in a variety of applications including in vivo applications such as phototherapy.
PCT/EP2014/072623 2013-10-24 2014-10-22 Upconverting vesicles and uses WO2015059180A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201318787A GB201318787D0 (en) 2013-10-24 2013-10-24 Upconverting vehicles and uses
GB1318787.7 2013-10-24

Publications (3)

Publication Number Publication Date
WO2015059180A2 WO2015059180A2 (en) 2015-04-30
WO2015059180A3 true WO2015059180A3 (en) 2015-06-18
WO2015059180A9 WO2015059180A9 (en) 2016-05-26

Family

ID=49767086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/072623 WO2015059180A2 (en) 2013-10-24 2014-10-22 Upconverting vesicles and uses

Country Status (2)

Country Link
GB (1) GB201318787D0 (en)
WO (1) WO2015059180A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111732950B (en) * 2020-07-28 2020-11-10 苏州科技大学 Azaanthracene derivative TTA-UC weak light up-conversion system and preparation method and application thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004310A1 (en) * 2015-07-02 2017-01-05 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
GB201603296D0 (en) 2016-02-25 2016-04-13 Ucl Business Plc Chemotactic,drug-containing polymersomes
GB201604553D0 (en) 2016-03-17 2016-05-04 Ucl Business Plc Fumarate polymersomes
US11026891B2 (en) 2016-08-16 2021-06-08 Eth Zurich Transmembrane pH-gradient polymersomes and their use in the scavenging of ammonia and its methylated analogs
EP3668547A4 (en) * 2017-08-17 2021-05-12 The Government of the United States of America, as represented by the Secretary of the Navy Zinc phthalocyanine and perylene co-loaded multifunctional nanoparticles for photodynamic therapy
US11078217B2 (en) * 2017-09-05 2021-08-03 University Of Massachusetts Triplet-triplet annihilation upconversion system, and compositions and methods thereof for drug delivery
CN110945076B (en) 2017-09-12 2023-10-17 苏黎士联邦理工大学 Transmembrane pH-gradient polymer vesicles for quantification of ammonia in body fluids
CN109966513B (en) * 2017-12-28 2022-05-17 北京大学 Preparation method and application of multifunctional microbubble integrating ultrasonic/fluorescent bimodal imaging and photodynamic therapy/chemotherapy
US11559586B2 (en) 2018-05-22 2023-01-24 Children's Medical Center Corporation Nanoparticles for treatment of choroidal neovascularization and other indications
KR20210096163A (en) * 2018-11-27 2021-08-04 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Photon Upconversion Nanocapsules for 3D Printing and Other Applications
WO2021071876A1 (en) * 2019-10-10 2021-04-15 University Of Massachusetts Photolytic compounds and triplet-triplet annihilation mediated photolysis
CN111748341B (en) * 2020-06-30 2023-06-16 苏州科技大学 Phenothiazine weak light up-conversion system and preparation method and application thereof
US11794177B2 (en) 2020-08-07 2023-10-24 International Business Machines Corporation Surface-modified light upconversion silica particles
CN112226230B (en) * 2020-10-30 2024-05-24 中国科学院理化技术研究所 Hydrophilic solid up-conversion luminescent material, preparation method thereof and application thereof in photolysis water hydrogen production reaction
WO2022120059A1 (en) * 2020-12-02 2022-06-09 The Truestees Of Columbia University In The City Of New York Photon upconversion biomaterials, micelle and nanoparticles for three-dimensional (3d) optogenetics
CN115011328B (en) * 2022-04-20 2024-01-23 中国科学院理化技术研究所 Luminescent material based on saccharide oxygen-blocking matrix, preparation and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156062A1 (en) * 2001-04-11 2002-10-24 Boch Ronald Erwin Drug delivery system for hydrophobic drugs
WO2012052821A1 (en) * 2010-10-18 2012-04-26 Universiteit Leiden Light induced drug release

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067839B1 (en) 2007-12-04 2013-03-20 Sony Corporation A device for modifying the wavelenght range of a spectrum of light

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156062A1 (en) * 2001-04-11 2002-10-24 Boch Ronald Erwin Drug delivery system for hydrophobic drugs
WO2012052821A1 (en) * 2010-10-18 2012-04-26 Universiteit Leiden Light induced drug release

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREY TURSHATOV ET AL: "Micellar carrier for triplettriplet annihilation-assisted photon energy upconversion in a water environment;Micellar carrier for triplettriplet annihilation-assisted photon energy upconversion in a water environment", NEW JOURNAL OF PHYSICS, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 13, no. 8, 31 August 2011 (2011-08-31), pages 83035, XP020209037, ISSN: 1367-2630, DOI: 10.1088/1367-2630/13/8/083035 *
QIAN LIU ET AL: "A General Strategy for Biocompatible, High-Effective Upconversion Nanocapsules Based on Triplet-Triplet Annihilation", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 13, 3 April 2013 (2013-04-03), pages 5029 - 5037, XP055182894, ISSN: 0002-7863, DOI: 10.1021/ja3104268 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111732950B (en) * 2020-07-28 2020-11-10 苏州科技大学 Azaanthracene derivative TTA-UC weak light up-conversion system and preparation method and application thereof

Also Published As

Publication number Publication date
WO2015059180A2 (en) 2015-04-30
GB201318787D0 (en) 2013-12-11
WO2015059180A9 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
WO2015059180A3 (en) Upconverting vesicles and uses
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016016143A (en) Substituted [1,2,4]triazole compounds.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
PH12015500900B1 (en) A stabilized pemetrexed formulation
WO2015069697A3 (en) Combination therapy
IN2014DN06104A (en)
PH12015502118A1 (en) Pyridin-4-yl derivatives
IN2015DN03998A (en)
CO7160080A2 (en) Lipid compositions of racecadot
WO2016011324A3 (en) 5'-triphosphate oligoribonucleotides
WO2014108288A3 (en) Substituted imidazole and (1,2,4)triazole compounds as fungicides
TN2016000490A1 (en) Naphthyridinedione derivatives.
WO2014172363A3 (en) Combretastatin analogs
MX365192B (en) Bendamustine derivatives and related compounds, and medical use thereof cancer therapy.
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
UA86446U (en) Compound 1,1'-(2"-bromo-2"-chloroethenyl)-bis-(uracil) with potential physiological properties
TH114066B (en) table
TH122934B (en) Headphones
TH52266S1 (en) Medical equipment
TH133478S (en) Medical equipment
UA86449U (en) Compound 1,1'-(2"-bromo-2"-chloroethenyl)-bis-(5-nitrouracil) with potential physiological properties
UA81916U (en) Compound 1,1'-(2"-bromo-2''-chloroethenyl)-bis-(imidazole) with potential physiological properties

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14789230

Country of ref document: EP

Kind code of ref document: A2